“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in USD
Last close As at 09/06/2023
USD2.03
▲ 0.06 (3.05%)
Market capitalisation
USD31m
Immix Biopharma’s lead asset, IMX-110, is being investigated in a Phase Ib/IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumors in combination with the ICI tislelizumab. Immix also has a pre-clinical pipeline based on the TSTx technology.
With IMX-110 Immix is targeting the soft tissue sarcoma market, a rare cancer with c 13,000–16,000 new cases reported in the United States each year and limited safe and effective treatment options. IMX-110’s combination study may further expand the drug’s offering into new indications.
Managing Director - Head of Content, Healthcare
Dr Ilya Rachman
CEO
Gabriel Morris
CFO
Forecast net debt (US$m)
15.1
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (14.3) | 2.0 | (9.0) |
| Relative | (17.5) | (5.2) | (12.7) |
| 52 week high/low | US$3.1/US$0.8 |
Immix Biopharma is a clinical-stage biopharmaceutical company focused on the development of its SMARxT tissue-specific platform producing tissue-specific therapeutics (TSTx). Its lead clinical asset, IMX-110, is being investigated for the treatment of soft tissue sarcoma, where interim results from its Phase Ib trial have, so far, demonstrated positive safety and efficacy profiles. Management intends to initiate a Phase IIa of the study in first-line soft tissue sarcoma in 2023. In Q422 Immix reported dosing of the first two patients in a Phase Ib/IIa study, investigating the use of IMX-110 in combination with tislelizumab in the treatment of solid tumors. We expect rolling data readouts across both studies throughout 2023. Immix Biopharma’s CAR-T therapy NXC-201 continues to demonstrate high response rates in multiple myeloma and AL amyloidosis from the Phase I/II NEXICART-1 study.
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 0.0 | (1.4) | (1.3) | (35.91) | N/A | N/A |
| 2022A | 0.0 | (8.2) | (7.7) | (55.49) | N/A | N/A |
| 2023E | 0.0 | (10.9) | (10.5) | (71.81) | N/A | N/A |
| 2024E | 0.0 | (14.4) | (14.0) | (93.33) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
